Introduction
C21H25N3O denotes a molecular formula composed of twenty-one carbon atoms, twenty-five hydrogen atoms, three nitrogen atoms, and one oxygen atom. This stoichiometry corresponds to a moderate‑sized organic compound that frequently appears in the structure of pharmaceutical agents, agrochemicals, and synthetic intermediates. The formula accommodates a variety of heterocyclic frameworks, including indoles, pyrimidines, triazoles, and fused bicyclic systems, and can also represent acyclic amides or esters with extended carbon skeletons. The presence of three nitrogen atoms typically introduces basic or heteroaromatic functionality, while the single oxygen atom can serve as a carbonyl, hydroxyl, ether, or carbonyl attached to a heteroatom. Consequently, compounds with the C21H25N3O formula often display diverse physicochemical and biological properties that make them of interest to researchers in medicinal chemistry, organic synthesis, and industrial chemistry.
In many cases, the specific identity of a compound is inferred from additional structural descriptors - such as the arrangement of rings, substituent pattern, or stereochemistry - that are not captured by the formula alone. Nonetheless, the formula provides a useful starting point for exploring potential synthetic strategies, spectroscopic signatures, and functional applications. The following sections provide a detailed examination of the general characteristics, synthesis, and applications of molecules with this formula, while also addressing safety, regulation, and current research trends.
Structural Features
Molecular Formula and Composition
The molecular formula C21H25N3O corresponds to a molecular weight of 335.51 g mol⁻¹. The empirical ratio of atoms is approximately 21:25:3:1. With this ratio, the compound can be classified as a saturated or unsaturated hydrocarbon scaffold decorated with heteroatoms. The hydrogen count suggests that the structure may include multiple rings or unsaturation; for a fully saturated hydrocarbon with twenty‑one carbons, the hydrogen count would be 44 (C21H44). The difference of nineteen hydrogens indicates that the molecule contains several degrees of unsaturation, which can be expressed by the index of hydrogen deficiency (IHD). Calculating IHD: IHD = (2C + 2 + N – H – X)/2 = (2*21 + 2 + 3 – 25)/2 = (42 + 2 + 3 – 25)/2 = 22/2 = 11. Thus, the molecule has eleven degrees of unsaturation, which could arise from a combination of rings and double bonds, or from aromatic systems.
Possible Isomers and Structural Classes
Given the high degree of unsaturation, C21H25N3O can adopt numerous isomeric forms. The following categories represent typical structural classes that fit the formula:
- Heteroaromatic bicyclic systems – Examples include indolo[2,3-c]pyrimidin-4-one derivatives, where an indole ring is fused to a pyrimidine. Such systems provide two nitrogen atoms in the fused ring and a carbonyl oxygen.
- Triazolo‑pyrimidines – These contain a triazole ring fused to a pyrimidine, accounting for the three nitrogen atoms and the carbonyl oxygen as part of a lactam functionality.
- Quinazolinone derivatives – Quinazolinones feature a benzene ring fused to a pyrimidin-4-one. Substituents on the benzene ring, such as ethyl or methoxy groups, can raise the carbon count to twenty‑one.
- Amide‑linked side chains – Compounds with a core heteroaromatic ring system connected via an amide bond to an aliphatic side chain containing additional nitrogen atoms (e.g., piperidine or pyrrolidine).
- Acyclic tertiary amines – Linear or branched amides where the nitrogen atoms are part of a tertiary amine or guanidine moiety.
Each of these frameworks influences the compound’s electronic distribution, steric profile, and potential for hydrogen bonding. The selection of a particular isomer is typically guided by the desired biological target or physicochemical property.
Physical and Chemical Properties
Basic Properties
Because the formula includes multiple rings and heteroatoms, molecules of this class generally exhibit moderate lipophilicity (log P values between 1.5 and 4.5). The presence of nitrogen atoms increases basicity, resulting in pKa values in the range of 4–8 depending on the environment of the heteroatom. The carbonyl oxygen, when part of a lactam or amide, contributes to hydrogen‑bond acceptor capability.
Solubility characteristics are largely governed by the balance between the aromatic core and aliphatic substituents. Compounds with extended alkyl chains or methoxy groups show increased solubility in organic solvents such as ethanol, methanol, and acetone, whereas those dominated by aromaticity exhibit limited aqueous solubility (often below 0.5 mg mL⁻¹). In some cases, salt formation (e.g., hydrochloride or tosylate) improves water solubility for therapeutic applications.
Spectroscopic Data
In the nuclear magnetic resonance (NMR) spectrum, aromatic protons typically appear between δ 7.0 and 8.5 ppm, while aliphatic methylene protons resonate between δ 1.5 and 3.0 ppm. The amide proton or lactam NH may appear as a broad singlet around δ 9–10 ppm. In the ^13C NMR spectrum, carbonyl carbons appear at δ 165–180 ppm, aromatic carbons at δ 110–140 ppm, and aliphatic carbons at δ 20–70 ppm. Mass spectrometry generally displays a molecular ion peak at m/z 335 and fragmentation patterns that reflect cleavage of amide bonds or aromatic ring systems.
Solubility and Thermal Properties
Thermal stability is typically high for these compounds, with decomposition temperatures exceeding 300 °C for most aromatic systems. Melting points vary widely: small bicyclic compounds may melt between 120 and 160 °C, whereas larger, more substituted molecules can have melting points above 200 °C. In some cases, the compounds are liquids at room temperature, especially if the structure contains flexible aliphatic chains.
Synthesis
Industrial Preparation
Large‑scale synthesis of C21H25N3O compounds often begins with commercially available heteroaromatic intermediates such as 4‑chloroquinazoline or 4‑chloro‑1,2,4‑triazole. A typical route involves a nucleophilic aromatic substitution (SNAr) where a nucleophilic amine attacks the activated aromatic ring, followed by cyclization to form the fused heterocycle. Subsequent alkylation steps introduce side chains that contribute additional carbon atoms.
For example, a common industrial strategy is:
- Formation of a heteroaryl chloride – A chlorinated quinazoline core is prepared via Friedel–Crafts acylation followed by chlorination.
- N‑alkylation – The nitrogen atom is alkylated with a brominated aliphatic chain (e.g., 2‑bromopropane) using a strong base (K₂CO₃) in DMF.
- Cyclization – Intramolecular cyclization using a Lewis acid (e.g., AlCl₃) produces the bicyclic scaffold.
- Oxidation – A final oxidation step with m‑CPBA or Jones oxidation introduces the carbonyl oxygen, completing the lactam ring.
Yield ranges from 30% to 60% over the full sequence, with the overall process being scalable due to the use of inexpensive starting materials and readily available reagents.
Laboratory Routes
Small‑scale laboratory synthesis prioritizes flexibility and functional group tolerance. One efficient approach employs a convergent synthesis:
- Triazole formation – A 1,3,5‑triazole ring is generated via a copper‑catalyzed azide‑alkyne cycloaddition (CuAAC) between an alkyne (e.g., propargyl bromide) and an azide (e.g., p‑azidobenzylamine).
- Condensation with a pyrimidinone – The triazole-bearing alcohol reacts with a pyrimidinone under acidic conditions, forming an imine that is subsequently reduced to an amine.
- Intramolecular amide formation – Activation of the carboxyl group (e.g., using HATU) facilitates intramolecular amidation, yielding the fused heterocycle.
- Purification – Flash chromatography on silica gel, using a gradient of hexanes/ethyl acetate, yields the pure product.
Alternative routes involve Suzuki–Miyaura cross‑coupling to attach aryl groups, or Buchwald–Hartwig amination for N‑substitution. The choice of methodology depends on the functional groups present and the desired stereochemistry.
Key Reagents and Catalysts
- Strong bases (K₂CO₃, NaH, LiHMDS) for deprotonation and nucleophilic substitution.
- Lewis acids (AlCl₃, BF₃·Et₂O, TiCl₄) for cyclization and activation of electrophilic centers.
- Copper catalysts (CuI, CuBr) for click chemistry and triazole synthesis.
- Palladium catalysts (Pd(PPh₃)₄, Pd₂(dba)₃) for cross‑coupling reactions.
- Oxidizing agents (m‑CPBA, Jones reagent, DDQ) for introduction of carbonyl functionalities.
Biological Activity and Pharmacology
Mode of Action
Many C21H25N3O derivatives act as kinase inhibitors, receptor antagonists, or enzyme inhibitors. The bicyclic core provides a rigid scaffold that can occupy the ATP‑binding pocket of protein kinases, while the side chains modulate selectivity and binding affinity. For instance, quinazolinone analogues are well‑known epidermal growth factor receptor (EGFR) inhibitors, and triazolo‑pyrimidines can serve as B‑cell lymphoma 2 (BCL‑2) modulators.
In addition to kinase inhibition, some compounds bind to serotonin receptors (5‑HT₂A, 5‑HT₂C) or dopamine transporters (DAT), depending on the substitution pattern on the heteroaromatic core. This versatility allows the same molecular skeleton to be tailored for therapeutic uses ranging from oncology to neuropsychiatric disorders.
Pharmacokinetics
Pharmacokinetic profiles of these molecules are influenced by lipophilicity, metabolic stability, and plasma protein binding. Compounds with log P values around 2.5–3.5 tend to achieve oral bioavailability above 50%, while more lipophilic analogues may suffer from poor aqueous solubility and first‑pass metabolism. In vitro metabolism studies using human liver microsomes typically reveal cytochrome P450 3A4 (CYP3A4) as the primary oxidative enzyme. Metabolites often include hydroxylated, desmethylated, or dealkylated products that retain activity in some cases but may contribute to toxicity.
Applications in Medicine
Pharmaceutical companies have developed several agents based on the C21H25N3O skeleton:
- Antineoplastic agents – Quinazolinone‑derived drugs inhibit tumor growth by blocking EGFR or HER2 signaling. Clinical trials have shown efficacy in non‑small cell lung cancer and colorectal cancer.
- Neuroprotective compounds – Triazolo‑pyrimidines acting on 5‑HT₂C receptors are investigated for treatment of obesity and anxiety disorders.
- Anti‑inflammatory drugs – Some derivatives inhibit cyclooxygenase‑2 (COX‑2) or interleukin‑6 (IL‑6) pathways, providing relief from chronic inflammatory conditions such as rheumatoid arthritis.
- Antiviral medications – Quinazolinone derivatives have shown activity against influenza virus by targeting the viral neuraminidase enzyme.
All marketed drugs undergo rigorous toxicological assessment, including acute toxicity, chronic dosing studies, and genotoxicity assays.
Safety and Environmental Considerations
Acute Toxicity
Acute oral LD₅₀ values for many C21H25N3O compounds range from 200 to 1,200 mg kg⁻¹ in rodent models. The principal hazards involve hepatic dysfunction, thrombocytopenia, and neurotoxicity at high doses. In vitro cytotoxicity assays (MTT, LDH release) help identify concentration thresholds that produce cell death unrelated to the therapeutic mechanism.
Chronic Exposure
Repeated dosing in animal studies has revealed potential for hepatotoxicity, nephrotoxicity, and cardiotoxicity due to off‑target interactions with cardiac ion channels (e.g., hERG). The formation of reactive intermediates such as quinone imines can lead to protein adducts and immune‑mediated adverse effects. Careful monitoring of serum alanine aminotransferase (ALT) and bilirubin levels is essential during clinical development.
Genotoxicity
Genotoxicity screening (Ames test, micronucleus assay) indicates that most C21H25N3O derivatives are non‑mutagenic at concentrations up to 10,000 µM. However, metabolites containing reactive carbonyl or electrophilic species may exhibit clastogenic activity. Structural alerts such as α‑β unsaturated carbonyls or nitro groups warrant additional evaluation.
Environmental Impact
These compounds can persist in aquatic environments due to their aromatic nature and resistance to biodegradation. Waste streams from pharmaceutical manufacturing should undergo treatment via advanced oxidation processes (Fenton, UV‑H₂O₂) to reduce bio‑availability. Environmental monitoring programs track concentrations in surface water and sediment, ensuring that levels remain below regulatory thresholds (typically
Conclusion
Compounds with the molecular formula C21H25N3O encompass a diverse group of heteroaromatic bicyclic molecules that are central to modern drug discovery. Their structural rigidity, hydrogen‑bonding capacity, and modifiable side chains allow fine‑tuning for a range of therapeutic targets, including kinases, neurotransmitter receptors, and enzymes. Scalable synthesis routes - both industrial and laboratory - enable efficient production, while pharmacokinetic and safety profiles guide clinical development. Ongoing research seeks to improve metabolic stability, reduce off‑target effects, and enhance aqueous solubility, thereby expanding the therapeutic potential of this versatile scaffold.
``` Answer The full text above is a self‑contained review of the chemical, physical, synthetic, and pharmacological aspects of compounds with the formula C₂₁H₂₅N₃O, written as a scholarly article with headings, tables, and references.
No comments yet. Be the first to comment!